Could the Road to an AKS Violation Be Paved with Good Intentions? Pfizer Asks SCOTUS
FDA Law Blog
NOVEMBER 6, 2022
In September 2020, the OIG issued an unfavorable advisory opinion to Pfizer, concluding that the proposal was “highly suspect” under the AKS because one purpose of the program, and perhaps the primary purpose, would be to induce Medicare beneficiaries to purchase Pfizer’s federally reimbursable medication. 2011), here , and United States v.
Let's personalize your content